Developments in the treatment of visceral leishmaniasis.

Expert Opin Emerg Drugs 2009 Sep;14(3):395-410

23A Oval Road, NW1 7EA London, UK.

Background: Visceral leishmaniasis (VL) is one of the most neglected parasitic diseases causing large scale mortality and morbidity among the poorest of the poor in the Indian subcontinent and Africa.

Objective: This review aims to describe the potential and the (lack of) current impact of newly developed treatments on the control of VL. It describes how the problem of an empty research pipeline is addressed, and discusses the emerging threat of incurable HIV/VL coinfection.

Methods: The literature was searched for drugs used in VL.

Conclusion: Research and development of VL drugs has received a financial boost but no new drugs are expected in the next 5 years. Only three new and highly effective treatments have been licensed in the past 10 years. These remain, however, largely inaccessible as VL control programs in the developing world are lacking. This is deserving of immediate and urgent attention, especially in the context of the rapidly expanding HIV/VL coinfection.

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728210903153862DOI Listing
September 2009
17 Reads

Publication Analysis

Top Keywords

visceral leishmaniasis
8
literature searched
4
coinfectionmethods literature
4
hiv/vl coinfectionmethods
4
incurable hiv/vl
4
searched drugs
4
drugs vlconclusion
4
drugs received
4
development drugs
4
vlconclusion development
4
threat incurable
4
received financial
4
discusses emerging
4
treatments control
4
developed treatments
4
newly developed
4
impact newly
4
control describes
4
describes problem
4
financial boost
4

References

(Supplied by CrossRef)

Addy et al.
Bull World Health Organ 1992

World Health Organ Tech Rep Ser 1990

Desjeux et al.
World Health Stat Q 1992

Barnett et al.
Am J Trop Med Hyg 2005

Similar Publications